SAR443122

DRUG3 trials

Sponsors

Sanofi

Conditions

Colitis UlcerativeCorona Virus InfectionCutaneous Lupus Erythematosus

Phase 1

A Phase 1b Trial to Evaluate Safety and Effect of SAR443122 on Immune System in Severe COVID-19

CompletedNCT04469621

SanofiCorona Virus Infection

Start: 2020-07-17End: 2020-10-23Updated: 2025-09-23

Phase 2

Proof of Concept Study of SAR443122 in Patients With Cutaneous Lupus Erythematosus

CompletedNCT04781816

SanofiCutaneous Lupus Erythematosus

Start: 2021-04-01End: 2023-06-26Updated: 2025-08-27

Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis

Active, not recruitingNCT05588843

SanofiColitis Ulcerative

Start: 2022-11-25End: 2026-12-02Updated: 2026-04-27

Related Papers

Immunomodulatory and clinical effects of receptor-interacting protein kinase 1 (RIPK1) inhibitor eclitasertib (SAR443122) in patients with severe COVID-19: a phase 1b, randomized, double-blinded, placebo-controlled study

Respiratory Research2024-02-2815 citations

Safety, pharmacokinetics, and target engagement of a brain penetrant RIPK1 inhibitor, SAR443820 (DNL788), in healthy adult participants

Clinical and Translational Science2023-11-2826 citations

Late Breaking Abstract - Immunomodulatory and clinical effects of RIPK1 inhibitor SAR443122 in patients with severe COVID-19

2021-09-052 citations